Phase 2 Lung Cancer Trial, Recruiting NCT06448572 Sponsor: University Hospital, Lille Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06448572
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older (male or female)
  • You are in generally good physical condition and able to carry out everyday activities with little or no limitation
  • You have been diagnosed with advanced or metastatic non-small cell lung cancer (a type of lung cancer) that cannot be removed by surgery, and/or has spread to other parts of the body
  • Your cancer does not have certain specific genetic changes (called EGFR, ALK, ROS1, MET, HER2, RET, or BRAF mutations/fusions) — however, having a KRAS mutation is allowed (confirm with trial site)
  • You have already been treated with both a type of immunotherapy (called an anti-PD-1 or anti-PD-L1 drug) and platinum-based chemotherapy, and your last dose was given more than 15 days before starting this trial
  • Your cancer got worse within 6 months of starting the immunotherapy treatment
  • You have already received all standard treatments available for your cancer
  • Your cancer can be measured on scans using standard methods
  • Your blood, kidney, and liver test results meet specific minimum levels of health, checked within 3 days before starting the trial (confirm specific values with trial site)

Who may not be able to join:

  • You have a type of lung cancer called small cell lung cancer, or a mixed type that includes small cell lung cancer
  • You have brain or spinal fluid involvement from your cancer that is causing symptoms — however, if brain spread causes no symptoms and requires no significant steroid medication, you may still be eligible (confirm with trial site)
  • You have a weakened immune system, or you are taking steroid medication at a dose higher than the equivalent of 10mg of prednisone per day within 2 weeks before starting the trial (inhaled, nasal, or skin-applied steroids are allowed)
  • You have received a live vaccine (a vaccine made from a live weakened germ) within the last 30 days
  • You have had a fecal microbiota transplant (a procedure involving donor stool to change gut bacteria) within the last 3 months
  • You have serious uncontrolled heart problems, such as heart failure, irregular heartbeat, unstable chest pain, or a heart attack or stroke within the last 6 months
  • You have had a severe (grade 3 or higher) serious immune-related side effect from previous immunotherapy treatment
  • You have a history of, or currently have, lung inflammation (pneumonitis) or scarring of the lungs (interstitial lung disease) that required steroid treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 July 2024
Est. completion
1 October 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov